Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Paris November 28, 2019: Bio-Modeling Systems invited to the PolePharma event "Industrie du futur" to present its collaboration with L2F the EPFL AI company adding a third dimension to AI through the Giotto program.
  • 2019: PRESS RELEASE: Paris November 6, 2019: Bio-Modeling Systems updates its pipeline of therapies, diagnostics, and bioprocesses and invites you to meet its team at BioFit and Polepharma Bio-Production conferences.
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French   therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children in India.
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO of BMSystems, joins Bolero's Pharma/Health Advisory Board to strengthen their services and accelerate the convergence between clinical research and Real Life Data

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: for the World Autism Awareness Day.
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

CADI™ Discovery - Research Production

CADI™ Discovery programs to date: 5 Business Units in 9 domains and 6 CADI™ Therapies:

5 Business Units

  1. Mechanisms-Based Medicine
  2. Mechanisms-Based Cosmetics
  3. Mechanisms-Based Nutrition
  4. Mechanisms-Based Bio-Production
  5. Digital-Health & Behavior-Modeling

9  BMSystems' R&D domains


BMSystems' Therapeutics, Diagnostics, Bio-Production Pipeline

  • Infection-Immunology domain: Chronic Fatigue Syndrome / Gulf war Syndrome; Ebola virus ecology; Hepatitis C; Autoimmunity : Global concept.
  • Micorbiota /Microbiome domain: Skin, lung, gut, etc., ecology, physiology & metabolic mechanisms. GEMMA, Microbiota & Autism H2020 program, selected for 14 M€ funding.
  • CNS / PNS Inflammation domain: Psychiatric & neurologic treatment; Creutzfeldt-Jakob disease mechanisms; Alzheimer's Disease Mechanisms. Parkinson's Disease Treatment; Psychiatric inflammatory mechanisms; Fibromyalgia, facial pain; Pain (Central/Peripheral); Migraine Mechanisms; Multiple Sclerosis Mechanisms; Psychiatric disorders biomarkers.
  • Metabolism / Inflammation domain: Hypercholestemia Mechanisms; Diabetes type 2; New global concept for Diabetes type 1; Metabolic Syndrome
  • Cardiovascular Diseases domain: Atherosclerosis mechanisms.
  • Cancer / Inflammation domain: Breast cancer-Hras; Tamoxifen resistance; Specific Tumor Metastasis control; Global Tumor Metastasis control.
  • Tissue Differentiation domain: Müllerian regression Mechanisms; Adipocytes growth control.
  • Dermatology / Cosmetics / Inflammation domain: Skin Contact Allergy Mechanisms; Skin pigmentation Mechanisms; Skin pigmentation Modulation; Skin aging Mechanisms; Modulation of skin hydration; Modulation of the lipid constituents of the skin barrier; Novel Hair Loss Mechanisms.
  • Industrial Biotech domain: Program Synthons; Industrial Biotech; Full Human Protein Glycosylation in Yeast. 
  • Rare diseases/ Orphan diseases/ Orphan drugs based on CADI™ Discovery repositioning

7 CADI™ Combo-Therapies and 1 CADI™ Combo-Diagnostic and 2 CADI™ Bioproduction Progams (new internal classification)


  1. CADI-T1011 Multi-Resistance Infectious Diseases
  2. CADI-T1031 CFS Low-Grade Chronic Inflammation
  3. CADI-T1032 Gulf War Syndrome
  4. CADI-T2011 Attenuation of the Core Symptoms of Autism
  5. CADI-T3021 Parkinson's Disease
  6. CADI-T4021 Metabolic Syndrome
  7. CADI-T4031 Attenuation of Developmental Consequences of Children Malnutrition


  1. CADI-D3041 Alzheimer's Disease Early Diagnostics


  1. CADI-B8011 Program Synthons (16 molecules study)
  2. CADI-B8021: Full Human Protein Glycosylation in Yeast

14 CADI™ successes programs (partners/clients questions) to date:

For all details download our short Presentation

  1. Mechanisms of pathogenesis & clinical progression of Creutzfeldt-Jakob Disease;
  2. Mechanisms of anti-connexin agents for modulating the therapeutic effect of psychotropic and neurodegenerative drugs;
  3. Cellular & metabolic mechanisms associated with chronic anxiety;
  4. Novel antiglycemic mechanism;
  5. Anti-metastatic mechanisms of the RGD15 peptide;
  6. Mechanisms of Ras-mediated breast cancer oncogenesis;
  7. Mechanisms of breast cancer resistance to tamoxifen;
  8. Regression mechanisms of the Müllerian duct;
  9. Mechanisms of differential melanosome degradation;
  10. Context-dependent functions of OA1 protein;
  11. Context-dependent functions of OCA2 protein;
  12. Context-dependent functions of SLC45A2 (MATP) protein;
  13. Engineered bacteriophage banks and the control of multi-resistant pathogens;
  14. Bioproduction and hemisynthesis of 18-methyl eicosanoic acid;

IMPORTANT: We are not domain dependent, but smart data access dependant

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers